摘要
目的观察急性心肌梗死患者静脉注射粒细胞集落刺激因子(G-CSF)动员自体骨髓干细胞的可行性和安全性。方法自2008年1月至2009年6月收治的22例急性心肌梗死患者,入院后在常规急性心肌梗死治疗(药物治疗和介入治疗)的基础上给予静脉注射粒细胞集落刺激因子(G-CSF,商品名:惠尔血)10μg/(kg·day),连续5天。观察外周血干细胞动员过程中的不良反应。结果急性心肌梗死患者在外周血干细胞动员期间不良反应发生率为45.5%,其中低热为18.2%,骨痛为13.6%,高热为0.09%,1例因支架内血栓形成退出试验。结论急性心肌梗死患者静脉注射GCS-F动员自体骨髓干细胞是安全的。
Objective To evaluate the safety of autologous peripheral blood stem cells mobilization by intravenous injection of granulocyte colony stimulating factor （G-CSF） in patients with acute myocardial infarction （AMI）. Methods Twenty-two patients with AMI were received intravenous injection of G-CSF （10 g/kg/day） after PCI treatment for 5 days. During the period of treatment,attention was paid to the following side effects：bone pain,fever,gastrointestinal effects （nausea,vomit,coprostatis）,deterioration of angina or heart failure, reinfarction and restenosis in stent）. Results The incidence of complications during G-CSF treatment was 45.5% , including that of bone pain being of 13.6% , fever being of 27.2% , re-infarction being of 0.05. Conclusions In patients with AMI, intravenous injection of G-CSF to mobilize autologous peripheral blood stem cells is feasible and safe.
出处
《中国分子心脏病学杂志》
CAS
2009年第6期357-359,共3页
Molecular Cardiology of China
基金
上海市科委国际合作课题(课题号:2007-24)
